Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 12,150,770 | 7,862,340 | 7,598,139 | 6,455,542 | 5,838,755 |
| Depreciation Amortization | 1,366,768 | 1,042,459 | 958,578 | 881,360 | 848,584 |
| Accounts receivable | -2,063,292 | -1,404,247 | -2,053,822 | -432,330 | -318,687 |
| Accounts payable and accrued liabilities | 1,454,759 | 951,127 | 501,642 | -98,201 | -59,660 |
| Other Working Capital | 2,903,710 | -755,578 | -1,377,170 | -666,880 | 364,257 |
| Other Operating Activity | 725 | 3,474,298 | 3,123,133 | 1,819,403 | 339,374 |
| Operating Cash Flow | $15,813,440 | $11,170,400 | $8,750,500 | $7,958,893 | $7,012,622 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -690,862 | -413,614 | 186,465 | N/A | N/A |
| PPE Investments | -3,747,031 | -1,719,874 | -1,007,898 | -891,318 | -1,338,307 |
| Net Acquisitions | N/A | -1,001,820 | -2,908,825 | N/A | -450 |
| Purchase Of Investment | -39,349 | -23,930 | -1,131,678 | -60,054 | -67,005 |
| Sale Of Investment | 4,792 | N/A | N/A | 1,838 | 22,185 |
| Purchase Sale Intangibles | -1,900,668 | -369,151 | -167,055 | -2,490,419 | -344,620 |
| Other Investing Activity | -1,900,668 | -369,151 | -166,419 | -2,487,661 | -341,622 |
| Investing Cash Flow | $-6,373,118 | $-3,528,389 | $-5,028,355 | $-3,437,195 | $-1,725,199 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 1,588,044 | 3,525,656 | 870,482 | -111,076 |
| Debt Repayment | -213,008 | -1,929,017 | -1,064,220 | -145,540 | N/A |
| Common Stock Repurchased | -4,344,965 | -3,410,578 | -3,094,018 | -2,582,186 | -2,298,567 |
| Dividend Paid | -4,612,568 | -3,582,905 | -3,423,355 | -3,082,537 | -2,909,409 |
| Other Financing Activity | -1 | 1 | 1 | 0 | 0 |
| Financing Cash Flow | $-9,170,542 | $-7,334,455 | $-4,055,936 | $-4,939,781 | $-5,319,052 |
| Exchange Rate Effect | -17,279 | -33,701 | 94,028 | -69,859 | -1,049 |
| Beginning Cash Position | 1,837,216 | 1,517,810 | 1,945,157 | 2,360,965 | 2,342,787 |
| End Cash Position | 2,089,719 | 1,791,665 | 1,705,393 | 1,873,023 | 2,310,109 |
| Net Cash Flow | $252,503 | $273,854 | $-239,764 | $-487,942 | $-32,678 |
| Free Cash Flow | |||||
| Operating Cash Flow | 15,813,440 | 11,170,400 | 8,750,500 | 7,958,893 | 7,012,622 |
| Capital Expenditure | -3,747,031 | -1,719,874 | -1,007,898 | -892,390 | -1,338,907 |
| Free Cash Flow | 12,066,409 | 9,450,526 | 7,742,602 | 7,066,503 | 5,673,715 |